Business
Theialife Appoints Thomas Ruggia as President and Chief Executive Officer to Advance Phase-3 Ready Oral Myopia Therapy and Scale Ophthalmology Platform
DOVER, Del., April 23, 2026 (GLOBE NEWSWIRE) -- Theialife, a late-stage clinical company advancing innovative therapeutic solutions for ocular diseases, today announced the appointment of Thomas Ruggia as President and Chief Executive Officer. Mr. Ruggia, based in New Jersey, will lead development, operational and corporate strategy as the Company prepares for anticipated milestones including the planned initiation of Phase 3 development for Thealife’s lead candidate, ND10. The company’s co-foun
About this update from Alcon Ag
[{"type":"image","alt":"Theialife","displaySize":"","headline":null,"caption":"Theialife","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/64157cce52c84cb5aeb02a2034c4c6d7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IfcHCYumIp8TxTReaHnLIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4/https://media.zenfs.com/en/globenewswire.com/64157cce52c84cb5aeb02a2034c4c6d7","width":300,"height":70}},"lazy":false},{"type":"text","content":"DOVER, Del., April 23, 2026 (GLOBE NEWSWIRE) -- Theialife, a late-stage clinical company advancing innovative therapeutic solutions for ocular diseases, today announced the appointment of Thomas Ruggia as President and Chief Executive Officer. Mr. Ruggia, based in New Jersey, will lead development, operational and corporate strategy as the Company prepares for anticipated milestones including the planned initiation of Phase 3 development for Thealife’s lead candidate, ND10. The company’s co-founder, Sundeep Aurora, will continue to oversee scientific research and development and will serve as Chairman.","length":609,"tagName":"p"},{"type":"text","content":"Ruggia brings more than 25 years of leadership experience across ophthalmology, pharmaceutical, medical devices and consumer healthcare. He has held senior roles at global organizations including Johnson & Johnson, Alcon, and Novartis. Ruggia has deep expertise in advancing innovative ophthalmic drugs and devices from development through regulatory approval and commercialization across international markets, along with a demonstrated track record of scaling ophthalmology companies through financing, global launches and reimbursement execution. He joins Theialife from Samsara Vision, a privately-held, commercial-stage ophthalmic device company where he served as CEO since 2020.","length":689,"tagName":"p"},{"type":"text","content":"“We are approaching a critical inflection point as we prepare to initiate Phase 3 development of ND10 in myopia and we believe that Tom’s deep expertise in ophthalmology makes him ideally suited to lead the next phase of our corporate and clinical evolution,” said Sundeep Aurora, Co-founder of Theialife. “He has demonstrated an ability to lead through late-stage development, regulatory milestones and commercial launches, while simultaneously scaling organizati...